CVE-2026-21974: Oracle Life Sciences Central Designer · Information Exposure
Affects Oracle Life Sciences Central DesignerSource CVE Database V5
Not known to be exploited · CVSS 5.3 Medium.
Data as of 25 Oct 2026, 19:02 UTC
- EPSS
- 0.2% chance of exploitation in 30 days – higher than 16% of CVEsExploit Prediction Scoring System: the likelihood attackers will use this flaw soon.
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:N/A:NExploitation evidence
Disclosed: evidence found.
CVE published 20 Jan 2026
Detectable: no evidence on record.
No public nuclei template indexed
Weaponised: no evidence on record.
No public exploit code indexed in Metasploit or Exploit-DB
Exploited in the wildExploited: no evidence on record.
Not in CISA KEV and no source reports exploitation
Observed by OffSeq MirageSeen by Mirage: no evidence on record.
No attack traffic recorded by OffSeq Mirage sensors
A missing step is not evidence of safety. Sources: cve.org (opens in a new tab), the Metasploit, Exploit-DB and nuclei-templates index as of 2026-10-25.
What to do
Affected software
| Product | Affected | Fixed in |
|---|---|---|
| Oracle CorporationOracle Life Sciences Central Designer | Affected
| Fixed in– |
Mavencom.oracle/life-sciences-central-designerpkg:maven/com.oracle/life-sciences-central-designerOther threats | Affected
| Fixed in– |
Check your own hosts for these packages with threat-finder (opens in a new tab), our free open-source scanner.
AI-suggested
1. Monitor Oracle’s official channels for patches addressing CVE-2026-21974 and apply them promptly once released. 2. Restrict network access to Oracle Life Sciences Central Designer instances by implementing network segmentation and firewall rules to limit HTTP access only to trusted internal users or systems. 3. Employ web application firewalls (WAFs) to detect and block suspicious HTTP requests targeting the vulnerable endpoints. 4. Conduct regular security audits and vulnerability scans focused on Oracle Health Sciences applications to identify exposed instances. 5. Implement strict access controls and logging to monitor any unauthorized access attempts. 6. Where possible, disable or limit HTTP access in favor of more secure protocols or VPN access to reduce exposure. 7. Educate IT and security teams about the vulnerability specifics to ensure rapid response and incident handling. 8. Review and enhance data encryption and masking policies for sensitive data within the application to minimize impact if unauthorized read access occurs.
Description
Vulnerability in the Oracle Life Sciences Central Designer product of Oracle Health Sciences Applications (component: Platform). The supported version that is affected is 7.0.1.0. Easily exploitable vulnerability allows unauthenticated attacker with network access via HTTP to compromise Oracle Life Sciences Central Designer. Successful attacks of this vulnerability can result in unauthorized read access to a subset of Oracle Life Sciences Central Designer accessible data. CVSS 3.1 Base Score 5.3 (Confidentiality impacts). CVSS Vector: (CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:N/A:N).